Abstract: An optical adaptor for mounting to a receptacle to optically couple connectorized optical cables comprises a coupling element to provide a passageway for inserting a respective ferrule of a first and a second optical connector terminating a first and a second optical cable. The optical adaptor further comprises a mounting element to mount the first optical connector to the receptacle, the mounting element being configured to be insertable in the receptacle, and a fixing element to fix the mounting element to the receptacle. The mounting element is formed as a hollow body to receive the coupling element and configured to fix the coupling element to the receptacle.

Abstract: An optical adaptor for mounting to a receptacle to optically couple connectorized optical cables comprises an assembly of an optical interface to provide an optical path between a first and a second one of the connectorized optical cables to optically couple the first and the second connectorized optical cable. The optical adaptor further comprises a mounting element formed as a hollow body to mount the assembly of the optical interface. The assembly of the optical interface is configured to be insertable in the hollow body of the mounting element. The mounting element is configured to mechanically couple the first connectorized optical cable to the mounting element so that the first connectorized optical cable is optically coupled to the optical path.

Abstract: An optical adaptor for mounting to a receptacle to optically couple connectorized optical cables comprises a coupling element to provide a passageway for inserting a ferrule of a first optical connector to terminate a first one of the connectorized optical cables and a ferrule of a second optical connector to terminate a second one of the connectorized optical cables to optically couple the first and the second connectorized optical cable. The optical adaptor further comprises a mounting element being mountable to the receptacle to hold the optical adaptor. The mounting element is configured to receive the coupling element.

Abstract: An optical adaptor for mounting to a receptacle to optically couple connectorized optical cables comprises a coupling element to provide a passageway for inserting a respective ferrule of a first and a second optical connector terminating a first and a second optical cable. The optical adaptor further comprises a mounting element to mount the first optical connector to the receptacle, the mounting element being configured to be insertable in the receptacle, and a fixing element to fix the mounting element to the receptacle. The mounting element is formed as a hollow body to receive the coupling element and configured to fix the coupling element to the receptacle.

Abstract: An optical adaptor for mounting to a receptacle to optically couple connectorized optical cables comprises a coupling element to provide a passageway for inserting a ferrule of a first optical connector to terminate a first one of the connectorized optical cables and a ferrule of a second optical connector to terminate a second one of the connectorized optical cables to optically couple the first and the second connectorized optical cable. The optical adaptor further comprises a mounting element being mountable to the receptacle to hold the optical adaptor. The mounting element is configured to receive the coupling element.

Abstract: An optical adaptor for mounting to a receptacle to optically couple connectorized optical cables comprises an assembly of an optical interface to provide an optical path between a first and a second one of the connectorized optical cables to optically couple the first and the second connectorized optical cable. The optical adaptor further comprises a mounting element formed as a hollow body to mount the assembly of the optical interface. The assembly of the optical interface is configured to be insertable in the hollow body of the mounting element. The mounting element is configured to mechanically couple the first connectorized optical cable to the mounting element so that the first connectorized optical cable is optically coupled to the optical path.

Abstract: A method of manufacturing an assembly to couple an optical fiber to an opto-electronic component includes providing the optical fiber having an end section with a front face to couple light in and out of the optical fiber, providing a housing to encase the end section of the optical fiber. The housing is formed with an opening to receive the optical fiber. The method further includes inserting the optical fiber in the opening such that the end section of the optical fiber is disposed inside the housing, attaching the optical fiber to a surface of the housing arranged to form a boundary of the opening, and aligning the front face of the optical fiber to the opto-electronic component.

Abstract: The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target C4.4a, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures.

Abstract: The present patent application relates to novel binder-drug conjugates (ADCs) of N,N-dialkylauristatins directed against the target epidermal growth factor receptor (EGFR, gene ID 1956), effective metabolites of these ADCs, methods for producing these ADCs, use of these ADCs for treatment and or prevention of diseases as well as the use of these ADCs to produce pharmaceutical drugs for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic diseases such as cancer, for example. Such treatments may be administered as monotherapy or in combination with other pharmaceutical drugs or other therapeutic measures.

Abstract: The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target C4.4a, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practiced as a monotherapy or else in combination with other medicaments or further therapeutic measures.

Abstract: The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target C4.4a, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures.

Abstract: An optical fiber having an end section with a front face to couple light in and out of the optical fiber is inserted in an opening of a housing to encase the end section of the optical fiber. The optical fiber is attached to a surface of the housing, wherein the surface forms a boundary of the opening. The front face of the optical fiber is aligned to the opto-electronic device such that light coupled out of the front face of the optical fiber is coupled into the opto-electronic device or light coupled out of the opto-electronic device is coupled into the optical fiber at the front face of the optical fiber.

Abstract: The present patent application relates to novel binder-drug conjugates (ADCs) of N,N-dialkylauristatins directed against the target epidermal growth factor receptor (EGFR, gene ID 1956), effective metabolites of these ADCs, methods for producing these ADCs, use of these ADCs for treatment and or prevention of diseases as well as the use of these ADCs to produce pharmaceutical drugs for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic diseases such as cancer, for example. Such treatments may be administered as monotherapy or in combination with other pharmaceutical drugs or other therapeutic measures.

Abstract: The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target mesothelin, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures.

Abstract: The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target C4.4a, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures.

Abstract: The goal of the invention is to increase the therapeutical activity of oncolytic NDV. This issue is solved by a Newcastle Disease Virus comprising a recombinant nucleic acid, wherein the nucleic acid codes for a binding protein that has a therapeutic activity when expressed by the virus-infected tumor cell. Binding proteins belong to the following group: A natural ligand or a genetically modified ligand, a recombinant soluble domain of a natural receptor or a modified version of it, a peptide-ligand, an antibody molecule and derivatives thereof or antibody-like molecules like ankyrin repeat molecules or derivatives thereof.

Abstract: The invention refers to a recombinant oncolytic RNA Newcastle Disease Virus for the treatment of a proliferative disease, comprising at least one transgene coding for an avian cytokine, wherein the recombinant oncolytic RNA Newcastle Disease Virus is obtainable from a velogenic or mesogenic oncolytic RNA Newcastle Disease Virus. Virus-mediated expression of the cytokine in the natural host cells leads to a reduced pathogenicity of the virus for avian species. Furthermore the virus genome can encode binding proteins, prodrug-converting enzymes or/and proteases. The selective expression of these molecules in virus-infected tumor cells increases the anti-tumor effect of the virus.

Abstract: Paramyxovirus from the group APMV3, APMV4, APMV5, APMV6, APMV7, APMV8, APMV9, Mapueravirus and Fer-de-Lance virus are described, which can be used for the production of a medicament for the treatment of tumors. The virus has a selectivity to kill human tumor cells but not human normal differentiated and human normal proliferating cells at the same dose. By genetic engineering the virus can be modified in such a way that one or more genes are added or are replaced by the homologous genes of a related paramyxovirus. By that method the anti-tumor activity of the resulting chimeric virus is enhanced compared to the parental virus.

Abstract: The goal of the invention is to increase the therapeutical activity of oncolytic NDV. This issue is solved by a Newcastle Disease Virus comprising a recombinant nucleic acid, wherein the nucleic acid codes for a binding protein that has a therapeutic activity when expressed by the virus-infected tumor cell. Binding proteins belong to the following group: A natural ligand or a genetically modified ligand, a recombinant soluble domain of a natural receptor or a modified version of it, a peptide-ligand, an antibody molecule and derivatives thereof or antibody-like molecules like ankyrin repeat molecules or derivatives thereof.

Abstract: A monobloc hollow shaft for transmitting torque, having two end portions, which, at their axial outer ends, are provided with shaft toothings for introducing torque, and having a central portion which, as compared to the end portions, has a smaller wall thickness, wherein, when torque is introduced via the shaft toothings, due to torsional forces a central part of the central portion of at least 25% of the length of the shaft is first of all uniformly plastically deformed.